Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Platelets ; 20(6): 367-75, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19811220

RESUMO

Microparticles (MPs) are blebs released from cellular surfaces during activation/apoptosis. They are procoagulant, pro-inflammatory and could contribute to pathogenesis of deep venous thrombosis (DVT). This study compared the number, cellular origin and procoagulant activity of MPs on DVT patients in different clinical situations: at diagnosis (n = 9, 5F/4M; mean age = 41.11), 1-3 years after warfarin withdrawal (n = 10, 7F/3M; mean age = 32.90), associated to antiphospholipid syndrome (APS; n = 11, 9F/2M; mean age = 33.82), or asymptomatic carriers of Factor V Leiden (FVL; n = 7, 7F/0M; mean age = 34.00) vs healthy controls (CTR). The quantification and characterization were performed by flow cytometry using CD235, CD61, CD45, CD31, CD14, CD45, anti-TF and Annexin V. The plasmatic procoagulant activity was investigated by prothrombin fragment 1 + 2 (F1 + 2) determination. The MPs procoagulant activity was analyzed by D-dimer (DD2) and Thrombin Generation Test (TGT) on a healthy pool of plasmas adjusted or not by their number (10,000 MPs). The MPs percentages were not different between the groups, but absolute number was increased in patients 1-3 years after warfarin withdrawal vs CTR (P = 0.02). There was no difference of the MPs cellular origin comparing patients to controls. TGT using 10,000 MPs was lower on these patients (P = 0.01). APS patients showed a reduction of plasmatic procoagulant activity (P = 0.004), but they were under warfarin therapy. DD2 in the presence of MPs, independently of its number, was higher in patients with DVT at diagnosis (P < 0.0001). MPs of patients with spontaneous DVT at diagnosis can promote coagulation activation demonstrated by increased DD2. Even the increased MPs from patients 1-3 years after thrombotic episode generated lower amount of thrombin, they can have a protective effect by activation of Protein C anticoagulant pathway.


Assuntos
Síndrome Antifosfolipídica/patologia , Fator V/metabolismo , Trombose Venosa/patologia , Adulto , Síndrome Antifosfolipídica/sangue , Síndrome Antifosfolipídica/genética , Testes de Coagulação Sanguínea , Estudos de Casos e Controles , Fator V/genética , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Citometria de Fluxo , Humanos , Lipoproteínas/metabolismo , Masculino , Tamanho da Partícula , Síndrome de Abstinência a Substâncias/sangue , Síndrome de Abstinência a Substâncias/patologia , Trombina/genética , Trombina/metabolismo , Trombose/sangue , Trombose/genética , Trombose/patologia , Trombose Venosa/sangue , Trombose Venosa/genética , Varfarina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...